Life Sciences
ACCOUNTING ADVISORY FOR LIFE SCIENCES
CFGI is a leading life sciences non-audit accounting advisory firm. With a track record of serving hundreds of life sciences clients and local leadership in biotech hubs like Boston, San Francisco, San Diego, and the tri-state area, CFGI boasts the largest and most experienced biotech accounting advisory team available. Since 2016, we have played a pivotal role in approximately 30% of all life sciences initial public offerings (IPOs) in the U.S. and have been involved in multiple cross-border offerings annually.
Our Commitment to Life Sciences
At CFGI, our primary goal is to empower life sciences companies to focus on what matters most to them: science and patient outcomes. We understand the intricacies of the industry, and our technical accounting experts and cross-functional consultants are here to navigate the complex terrain of accounting, finance, and reporting. We ensure that accounting complexities become a thing of the past, allowing our clients to meet crucial deadlines and milestones seamlessly.
Tailored Solutions for CFOs
CFOs in the life sciences industry encounter unique challenges that demand astute financial acumen and strategic foresight. These challenges include:
Operating with a skeleton accounting department requires careful resource allocation and workforce management for smooth financial operations.
CFOs often need to outsource certain operational and technical functions to focus on core financial strategies.
Meticulous scrutiny of contractual agreements is vital for compliance, risk mitigation, and maintaining financial integrity.
CFOs must make critical decisions regarding financial investments and technological advancements to drive sustainable growth.
Navigating these challenges demands expertise, adaptability, and a comprehensive understanding of the industry’s nuances – qualities that CFGI brings to the table.
Expertise Delivered by CFGI
CFGI specializes in delivering expertise tailored to the unique needs of the life sciences industry, including:
- Debt and Equity (ASC 470/480 and 815)
- Valuations of Complex Instruments
- Collaboration and Licensing Arrangements (ASC 606/808)
- Commercial Launch and Gross to Net Accounting
- Stock-Based Compensation (ASC 718)
- Leases (ASC 842)
- IPO Readiness and SEC Reporting
- Financial Statement Preparation
- Technical Accounting
- Tax Provision and Return Preparation
- R&D Tax Credit Analysis
- Public Company Process Optimization
- SOX 404 a/b and Controls Implementation
- Cybersecurity Assessment
- FP&A and Clinical Accrual Analysis
Recent Relevant Projects
Our recent projects exemplify our commitment to delivering impactful solutions:
- Assisted a biotech company with revenue and inventory assessment gearing up for commercial launch, finalizing revenue policies, and gross to net implications.
- Support a life sciences company with technical accounting in preparation for IPO readiness, continuing interim support with SEC reporting, month-end close, post-IPO system implementations, ERP upgrades, and SOX 404b compliance.
- Provided interim support for a life sciences company optimizing month-end close and R&D accrual lift.
- Conducted a convertible notes and preferred stock assessment for a life sciences company with embedded features and underlying warrant classifications.
- Offered stock-based compensation calculation and system implementation review for a life sciences company.
Clients
Connect With Our Leaders
Partner with CFGI to navigate the complexities of the life sciences industry with confidence. Contact us today to discover how we can be your strategic ally in achieving financial success and operational excellence.
Ryan Dolan
Senior Managing Partner
(978) 317-9398
rdolan@cfgi.com
Lindsi Scanlan
Managing Partner
(610) 613-7783
lscanlan@cfgi.com
Kelly Provost
Partner
(603) 321-4113
kprovost@cfgi.com
Keith Ouellette
Partner
(339) 223-0121
kouellette@cfgi.com
Melanie Kavanagh
Managing Partner
(781) 632-2011
mkavanagh@cfgi.com
